Literature DB >> 36269540

An Update on Diagnostic Laboratory Biomarkers for Multiple Sclerosis.

Marwa Kaisey1, Ghazal Lashgari2, Justyna Fert-Bober2, Daniel Ontaneda3, Andrew J Solomon4, Nancy L Sicotte2.   

Abstract

PURPOSE: For many patients, the multiple sclerosis (MS) diagnostic process can be lengthy, costly, and fraught with error. Recent research aims to address the unmet need for an accurate and simple diagnostic process through discovery of novel diagnostic biomarkers. This review summarizes recent studies on MS diagnostic fluid biomarkers, with a focus on blood biomarkers, and includes discussion of technical limitations and practical applicability. RECENT
FINDINGS: This line of research is in its early days. Accurate and easily obtainable biomarkers for MS have not yet been identified and validated, but several approaches to uncover them are underway. Continue efforts to define laboratory diagnostic biomarkers are likely to play an increasingly important role in defining MS at the earliest stages, leading to better long-term clinical outcomes.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Biomarkers; Diagnosis; Multiple Sclerosis

Year:  2022        PMID: 36269540     DOI: 10.1007/s11910-022-01227-1

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   6.030


  149 in total

Review 1.  Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice.

Authors:  Mark S Freedman; Giancarlo Comi; Nicola De Stefano; Frederik Barkhof; Chris H Polman; Bernard M J Uitdehaag; Lorenz Lehr; Bettina Stubinski; Ludwig Kappos
Journal:  Mult Scler Relat Disord       Date:  2013-07-31       Impact factor: 4.339

Review 2.  The tension between early diagnosis and misdiagnosis of multiple sclerosis.

Authors:  Andrew J Solomon; John R Corboy
Journal:  Nat Rev Neurol       Date:  2017-08-11       Impact factor: 42.937

3.  Neurofilament light chain as an indicator of exacerbation prior to clinical symptoms in multiple sclerosis.

Authors:  Keith R Edwards; Lore Garten; Judy Button; Judy O'Connor; Vineetha Kamath; Carol Frazier
Journal:  Mult Scler Relat Disord       Date:  2019-03-23       Impact factor: 4.339

Review 4.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Authors:  Alan J Thompson; Brenda L Banwell; Frederik Barkhof; William M Carroll; Timothy Coetzee; Giancarlo Comi; Jorge Correale; Franz Fazekas; Massimo Filippi; Mark S Freedman; Kazuo Fujihara; Steven L Galetta; Hans Peter Hartung; Ludwig Kappos; Fred D Lublin; Ruth Ann Marrie; Aaron E Miller; David H Miller; Xavier Montalban; Ellen M Mowry; Per Soelberg Sorensen; Mar Tintoré; Anthony L Traboulsee; Maria Trojano; Bernard M J Uitdehaag; Sandra Vukusic; Emmanuelle Waubant; Brian G Weinshenker; Stephen C Reingold; Jeffrey A Cohen
Journal:  Lancet Neurol       Date:  2017-12-21       Impact factor: 44.182

5.  Incidence of multiple sclerosis misdiagnosis in referrals to two academic centers.

Authors:  Marwa Kaisey; Andrew J Solomon; Michael Luu; Barbara S Giesser; Nancy L Sicotte
Journal:  Mult Scler Relat Disord       Date:  2019-02-02       Impact factor: 4.339

6.  Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.

Authors:  Lenka Novakova; Markus Axelsson; Mohsen Khademi; Henrik Zetterberg; Kaj Blennow; Clas Malmeström; Fredrik Piehl; Tomas Olsson; Jan Lycke
Journal:  J Neurochem       Date:  2016-11-29       Impact factor: 5.372

7.  PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation.

Authors:  Andrea C Tricco; Erin Lillie; Wasifa Zarin; Kelly K O'Brien; Heather Colquhoun; Danielle Levac; David Moher; Micah D J Peters; Tanya Horsley; Laura Weeks; Susanne Hempel; Elie A Akl; Christine Chang; Jessie McGowan; Lesley Stewart; Lisa Hartling; Adrian Aldcroft; Michael G Wilson; Chantelle Garritty; Simon Lewin; Christina M Godfrey; Marilyn T Macdonald; Etienne V Langlois; Karla Soares-Weiser; Jo Moriarty; Tammy Clifford; Özge Tunçalp; Sharon E Straus
Journal:  Ann Intern Med       Date:  2018-09-04       Impact factor: 25.391

8.  One hundred and fifty years ago Charcot reported multiple sclerosis as a new neurological disease.

Authors:  Bernard Zalc
Journal:  Brain       Date:  2018-12-01       Impact factor: 13.501

9.  Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.

Authors:  Giulio Disanto; Christian Barro; Pascal Benkert; Yvonne Naegelin; Sabine Schädelin; Antonella Giardiello; Chiara Zecca; Kaj Blennow; Henrik Zetterberg; David Leppert; Ludwig Kappos; Claudio Gobbi; Jens Kuhle
Journal:  Ann Neurol       Date:  2017-06       Impact factor: 10.422

10.  Blood neurofilament light levels segregate treatment effects in multiple sclerosis.

Authors:  Bénédicte Delcoigne; Ali Manouchehrinia; Christian Barro; Pascal Benkert; Zuzanna Michalak; Ludwig Kappos; David Leppert; Jon A Tsai; Tatiana Plavina; Bernd C Kieseier; Jan Lycke; Lars Alfredsson; Ingrid Kockum; Jens Kuhle; Tomas Olsson; Fredrik Piehl
Journal:  Neurology       Date:  2020-02-11       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.